The GO analysis highlighted the activation of different pathways, mainly related to EC, immune response, and programmed cell death, suggesting that targeting some of these up-regulated pathways (particularly those related to secreto-proteins/mucin dysfunction) may represent a potential therapeutic option for IPF. Here, MUC5AC is linked to idiopathic pulmonary fibrosis.